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Roberts syndrome (RS) is a developmental disorder characterized by tetraphocomelia and a broad spectrum of
additional clinical features. Most patients with RS exhibit characteristic cytogenetic phenotypes, which include an
abnormal appearance of pericentromeric heterochromatin on metaphase chromosomes, referred to as “hetero-
chromatic repulsion.” In the present study, we use complementation of this abnormal cytogenetic phenotype as a
means to identify a specific region of the normal human genome capable of rendering phenotypic correction. We
screened the entire human genome, using a transient chromosome-transfer assay, and demonstrated complementation
exclusively after the transfer of proximal chromosome 8p, a result subsequently confirmed by stable microcell-
mediated chromosome transfer. Additionally, homozygosity mapping was used to refine the interval of this com-
plementing locus to 8p21. The results are consistent with the notion that the single gene defect responsible for
heterochromatic splaying and developmental abnormalities maps to chromosome 8p21.
In 1919, John Roberts described a rare developmental
disorder, Roberts syndrome (RS [MIM 268300]) (Rob-
erts 1919), that is characterized by tetraphocomelia (sym-
metrical limb reduction) and a broad spectrum of ad-
ditional variably apparent characteristics that include
prenatal and postnatal growth retardation, craniofacial
abnormalities, cleft lip and palate, corneal clouding,
prominent phallus, and cardiac and renal abnormalities
(for a review, see the work of Van Den Berg and Francke
[1993a]). This disorder has also been referred to as “pseu-
dothalidomide syndrome,” since infants born to women
who took thalidomide during pregnancy had similar
limb malformations (Jurenka 1976). Although RS and
the SC phocomelia syndrome (MIM #269000) were
originally described as distinct entities, they are now con-
sidered to be a single disorder with significant clinical
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heterogeneity (Waldenmaier et al. 1978; Tomkins et al.
1979; Fryns et al. 1980; Zergollern and Hitrec 1982).
RS appears to be represented by two genetic comple-
mentation groups, designated “RS” and “RS.” Pa-
tients are classified into the two groups on the basis of
their cytogenetic and cellular phenotypes. Cells and cell
lines derived from patients with RS manifest a phe-
nomenon evident in mitotic chromosomes that has been
previously referred to as heterochromatic repulsion (HR),
heterochromatic splaying (HS), or premature centromere
separation (herein referred to as “HR”) (Freeman et al.
1974; Louie and German 1981). Additionally, RS cells
exhibit mild hypersensitivity to mitomycin C, cisplatin,
g radiation, and other DNA-damaging agents (Burns and
Tomkins 1989; Van Den Berg and Francke 1993b), as
well as cell-cycle abnormalities. Importantly, RS cell lines
propagated in culture, including nontransformed fibro-
blasts, also exhibit random chromosome loss and gain,
presumably the consequence of improper chromosome
segregation (Jabs et al. 1989). Hereafter, the RS com-
plementation group is designated as “RS.”
Microcell-mediated chromosome transfer (MMCT)
(McDaniel and Schultz 1992) is a technique whereby
normal human chromosomes are transferred from donor
to recipient cells via a microcell intermediate. Chromo-
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some-recipient clones are identified by selection for domi-
nant markers and are analyzed for complementation of
mutant recessive phenotypes (such as the HR associated
with RS cells). However, an exhaustive analysis of all
chromosomes for the identification of complementing
loci by use of this approach would be very labor inten-
sive. It would require the transfer of each tagged normal
human chromosome, selection and long-term propaga-
tion of clonal isolates, and characterization of each of
these clones for retention of the transferred chromo-
some and complementation of the relevant phenotype.
Additionally, this strategy necessitates the use of immor-
talized cell lines representing the syndrome and main-
tenance of the cellular phenotype(s) of interest. Finally,
with regard to the present study, initial experiments dem-
onstrated that SV40 transformation of a fibroblast cell
line (GM03913 [National Institute of General Medical
Sciences Human Genetic Cell Repository]) of a patient
with RS resulted in clones with an inconsistent HR phe-
notype, which compromised their utility in a comple-
mentation strategy (R.A.S. and L.D.M., unpublished
observations).
To circumvent the aforementioned limitations, a tran-
sient whole-cell–fusion complementation assay was de-
vised and was employed to introduce a limited number
of human chromosomes from normal cells into RS cells,
for rapid scoring for complementation of HR. The cell
lines used were RS lymphoblastoid cell lines R20 and
LB1 (Tomkins et al. 1979), Srsym1 (McDaniel et al.
2000), and Srsym2. The control donor cell line that was
used, SV40-transformed VA-13 (American Type Culture
Collection), was valuable because it contained both nor-
mal and rearranged copies of most chromosomes and
was female in origin. Microcells were obtained from the
donor cell line by treating cells in flasks with 25 mg/ml
colcemid solution (Invitrogen) for 48 h, followed by cen-
trifuging the flasks at 12,000 g for 1 h in the presence
of 4 mg/ml cytochalasin B (Sigma). Microcells were col-
lected and size selected by filtration and were fused with
RS lymphoblastoid cells from patient cell lines, in the
presence of 50% PEG 1500 (Roche), for 90 s. Ultimately,
R20 proved to be the most efficient recipient, and all
data reported are from fusions to that cell line. Com-
plementation of a male cell line (R20) with a female
donor afforded the opportunity to assess complemented
metaphase cells for the presence of the Y chromosome
as evidence that the metaphase originated from the R20
background. Fusion products were then grown for 48
h to allow complementation to occur in recipients that
had received the complementing chromosome. Cells were
grown for an additional 72 h, in the presence of hygro-
mycin B, at a dose that did not significantly reduce the
number of control metaphase cells but that lowered the
overall number of R20 metaphase cells by 80%. This
reduced the number of uncomplemented RS cells in the
population. Surviving metaphase cells were then har-
vested. Chromosome-specific paints were used for FISH,
to independently identify the copy number of each par-
ticular chromosome as well as to identify newly intro-
duced rearrangements in both complemented and un-
complemented metaphase cells on the same slide. HR in
RS cells is traditionally visualized by examination of
fixed metaphase chromosomes stained by conventional
C-banding techniques to highlight constitutive heter-
ochromatin (Rooney and Czepulkowski 1986). In the
present study, distamycin A (DA) with 4′-6-diamidino-
2-phenylindole (DAPI) staining (Verma 1995) was em-
ployed to facilitate analysis of the HR effect in a fluo-
rescence-based assay. DA/DAPI staining employed 50
mg/ml DA in PBS for 20 min. Slides were washed in PBS,
stained with 0.5 mg/ml DA/DAPI for 15 min, mounted
with Vectashield (Vector Laboratories). When DA and
DAPI are used together, AT-rich areas of constitutive
heterochromatin fluoresce in regions of chromosomes 1,
9, 15, 16, and distal Yq, which allows evaluation of HR
with the simultaneous use of FISH to identify the chro-
mosomes transferred.
Given that RS cells exhibit ongoing random chromo-
some loss and gain (Jabs et al. 1989), a numerical profile
for each chromosome was generated for R20 parental
cells by use of the same type of FISH studies employed
to characterize the fusion products. Large numbers of
complemented and uncomplemented metaphases were
generated and analyzed on single FISH slides. Despite
the aneuploid nature of the R20 cell line, our approach
provided sufficient data to assess whether overrepresen-
tation of a certain chromosome correlated with comple-
mentation. For nearly all chromosomes examined, the
distribution of copy number for a given chromosome
did not significantly vary among R20 parental, uncom-
plemented, and complemented metaphase cells (fig. 1A–
1C). With use of this chromosome-painting approach,
it was possible to rule out all autosomes, except chro-
mosome 8 (fig. 1D). None of the other chromosomes
displayed the increase in chromosome number in the
complemented cells that was observed in chromosome
8. Consistent with this assignment, it was also observed
that none of the complemented metaphases contained
only one chromosome 8.
In addition to association of complementation with
an increase in the numerical representation for a given
normal chromosome, the SV40-transformed VA-13 cell
line, used as the MMCT donor, offered structural re-
arrangements and deletions that could be identified in
fusion products for correlation with complementation.
BAC and YAC probes were localized to regions on the
p and q arms of chromosome 8. These probes and chro-
mosome 8 paints were then used to identify recurrent
rearrangements in VA-13 metaphases. With use of these
probes, it was noted that VA-13–derived 8p deletions
Figure 1 Profile of chromosome number in R20 parental cells, complemented cells, and uncomplemented cells after transient MMCT
and FISH. A, R20 parental cells. With the use of one chromosome paint on each slide, 100–150 cells were characterized for chromosome
number. B, Chromosome profile of uncomplemented metaphases after MMCT (150–500 metaphases scored). C, Chromosome profile of com-
plemented metaphases on the same slide as the metaphases shown in panel B (10–30 metaphases scored). A–C, Bar colors indicate the percentage
of metaphases with one (red), two (green), three (blue), four (purple), or five (orange) copies of each of the autosomes. D, Number of chromosome
8 sequences per metaphase in R20 parental, uncomplemented, and complemented metaphase cells in the same experiment. Chromosome 8 is
the only chromosome that displayed an increased number in complemented cells.
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Figure 2 Characterization of metaphases observed by transient complementation. A, R20 metaphase, stained by DA/DAPI, displaying
the HR phenotype in the constitutive heterochromatic regions of the autosomes. Yellow arrows indicate the HR phenotype in the heterochromatin
of the chromosomes. B, Summary of the results for rearrangements that did not yield complementation of the HR phenotype, displayed by
ideograms, DA/DAPI partial metaphases, and FISH. Yellow arrows indicate the uncomplementing transferred chromosome. Panels 1 and 2
show results with biotin-labeled chromosome 8 paint. Panel 3 shows results with biotin-labeled YAC 815d7 (8p11.21). All were detected with
avidin–fluorescein isothiocyanate (FITC). C, Complemented metaphase, with the smallest fragment of chromosome 8 (indicated by the red
arrow) detected by transient complementation assay probed with YAC 847b12 (8p12). Yellow arrows indicate the HR phenotype in
the heterochromatin of the chromosomes.
failed to render correction (fig. 2B). Conversely, with
retention of the p arm of chromosome 8, specifically with
those metaphase cells that retained 8p12 sequences cor-
responding to YAC 847b12 and some distal material,
results exhibited a 100% correlation with complemen-
tation. It was noted that the smallest complementing
chromosome was positive for hybridization with YAC
847b12 but retained little additional distal material on
the p arm of chromosome 8 (fig. 2C).
Collectively, the results of the transient complemen-
tation experiments are consistent with a map location
of the complementing gene for RS in or near 8p12. These
results predict that the stable transfer of chromosome 8
should correct the HR phenotype. To test this prediction,
a mouse A9 monochromosomal hybrid bearing a human
chromosome 8 that was “tagged” with a neomycin-re-
sistance gene (neor) was used as a donor for MMCT to
RS cells. GM03913 fibroblast cells were derived from
the same patient as the R20 lymphoblastoid cells. As
mentioned above, SV40-transformed GM03913 RS fi-
broblasts exhibited an unstable HR phenotype (R.A.S.
and L.D.M., unpublished results). However, we estab-
lished telomerase-immortalized GM03913 cells (reported
elsewhere and herein as “TERT-RBS”) (Ouellette et al.
2000) with a stable RS cellular phenotype, including
HR, hygromycin B sensitivity, and random chromosome
loss and gain. These cells were used as recipients for
stable MMCT. Stable clones were recovered, and it was
observed that one of eight clones was phenotypically com-
plemented for HR (fig. 3A). In contrast, no complemen-
tation was seen after a neo-tagged chromosome 15 was
introduced. These results confirm that chromosome 8
carries the complementing gene for RS. These comple-
mented cells also exhibited resistance to hygromycin B,
similar to that observed in control cells (data not shown).
Automated genotyping was used to evaluate sequences
transferred from the chromosome 8 mouse/human hy-
brid MCH904.11 into recipient TERT-RBS cells. The
seven uncomplemented clones and the single comple-
mented clone were tested with 29 polymorphic markers
spanning chromosome 8. Table 1 summarizes the allele
sizes represented by the chromosome 8 sequences that
are endogenous to the recipient cells and the one chro-
mosome 8 that was provided by the donor hybrid. In
this experiment, 27 of 29 markers were informative for
the newly introduced chromosome 8 sequences. Analysis
of the recovered clones revealed that the one comple-
mented clone (clone 17) retained all the markers for the
donated chromosome 8. Of the remaining clones, five
of seven shared a common breakpoint in 8p11.2, and
Figure 3 Stable introduction of chromosome 8 into TERT-RBS cells. Yellow arrows indicate the HR phenotype in the heterochromatin
of the chromosomes in the DA/DAPI-stained metaphases. A, Metaphase exhibiting complementation of the HR phenotype in clone 17. Chro-
mosome 8 paint, labeled with biotin and detected with avidin-FITC, reveals tetrasomy for chromosome 8 in the complemented metaphase, a
result consistent with the fact that most of the TERT-RBS cells were trisomic for chromosome 8 prior to MMCT. B, The uncomplemented
clone 18, probed using an chromosome 8 centromere probe directly labeled with Spectrum Orange. The red arrow indicates the contributed
chromosome 8, with a significant portion of the p arm deleted.
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Table 1
Allele Sizes in Parental Cell Lines and Clones from MMCT
MARKER
ALLELE SIZE(S) (BP) IN
MCH904.11 TERT-RBS
Clone
1 2 3 4 17 18 19 20
D8S264 155 151, 153 151, 153 151, 153 151, 153 151, 153 151, 153, 155 151, 153 151, 153 151, 153
D8S550 208 192, 194 192, 194 192, 194 192, 194 192, 194 192, 194, 208 192, 194 192, 194 192, 194
D8S1106 125 143 143 143 143 143 134, 125 143 143 143
D8S549 84 82 82 82 82 82 82, 84 82 82 82
D8S1145 270 273, 281 273, 281 273, 281 273, 281 273, 281 270, 273, 281 273, 281 273, 281 273, 281
D8S258 152 154, 156 154, 156 154, 156 154, 156 154, 156 152, 154, 156 154, 156 154, 156 154, 156
D8S282 265 267 267 267 267 267 265, 267 266 266 266
D8S1786 211 215 215 215 215 215 215, 211 215 215 215
D8S1752 156 145 145 145 145 145 145, 156 145 145 145
D8S1734 120 114 114 114 114 114 114, 118 114 114 114
D8S1725 266 268 268 268 268 268 266, 268 268 268 268
D8S1771 356 354 354 354 354 354 354, 356 354 354 354
D8S382 317 309 309 309 309 309 309, 317 309 309 309
D8S1048 204 204 204 204 204 204 204 204 204 204
D8S1839 175 175 175 175 175 175 175 175 175 175
D8S131 134 140 140 140 140 140 134, 140 140 140 140
D8S585 174 186 186 186 186 186 174, 186 186 186 186
D8S1820 111 119 119 119 119 119 119, 117 119 119 119
D8S1477 166 154 154, 166 154, 166 154, 166 154, 166 154, 166 154, 166 154 154
D8D505 115 113 113, 115 113, 115 113, 115 113, 115 113, 115 113, 115 113 113
D8S1121 118 115 115, 118 115, 118 115, 118 115, 118 115, 118 115, 118 115 115
D8S1821 142 165 142, 165 142, 165 142, 165 142, 165 142, 165 142, 165 142 142
D8S532 247 245 245, 247 245, 247 245, 247 245, 247 245, 247 245, 247 245 245
D8S1104 129 141 129, 141 129, 141 129, 141 129, 141 129, 141 129, 141 141 141
D8S1747 211 219 219, 211 219, 211 219, 211 219, 211 219, 211 219, 211 219 219
D8S1745 127 133 127, 133 127, 133 127, 133 127, 133 127, 133 127, 133 133 133
D8S1133 193 189 189, 192 189, 192 189, 192 189, 192 189, 192 189, 192 189 189
D8S1136 260 249 249 249, 260 249 249 249, 260 249 249 249
D8S1119 182 174 174, 182 174, 182 174, 182 174, 182 174, 182 174, 182 174 174
NOTE.—Numbers in bold italics represent cases in which the alleles from both R20 and the chromosome hybrid MCH904.11 were present
in the clone. Markers that were uninformative are underlined.
two of seven had none of the alleles of the donated chro-
mosome. FISH analysis confirmed the loss of distal 8p
(fig. 3B). Note that the recovery of neor clones bearing
this structure is consistent with a more proximal 8p lo-
cation of the neo-tag in the chromosome 8 present in
MCH904.11 hybrid cells (results documented by FISH
[data not shown]). The loss of the p arm of chromosome
8 during the process of MMCT may be due to the clas-
togenic effects of cytochalasin B (Kolber et al. 1990) or
to an event that may be stimulated by the amplification
of the neor gene during selection.
We performed a genomewide scan for homozygosity.
DNA from five unrelated patients with RS, patient S4134
and four previously mentioned patients (Tomkins et al.
1979), was amplified and analyzed for microsatellite
markers. Chromosomes 1–11 were completed, and no
loci were found to be homozygous in all patients, except
on chromosome 8. On the basis of the above evidence
for an RS complementing locus on 8p, we focused on
this chromosomal arm to further refine the location of
the complementing gene. In addition to known microsat-
ellites, some SNPs and predicted variable repeats (Fondon
et al. 1998) were used. The results presented in table 2
identify an interval of homozygosity, in all five patients
with RS, mapping to 8p21, with no evidence of an al-
ternative locus. Most patients exhibit homozygosity over
a common 8.9-Mb interval; one patient, S4134, was
homozygous for markers covering a 2.3-Mb region.
In summary, the results presented identify a single ge-
nomic interval on proximal chromosome 8p that is ca-
pable of complementing the HR phenotype and hygro-
mycin sensitivity of RS cells. The results of homozy-
gosity mapping confirmed the existence of an interval at
8p21 that is homozygous for all markers tested in five
patients with RS. The results are consistent with the
notion that the complementing locus for HR and the
gene defect in patients with RS are one and the same
and that it maps to chromosome 8p21.
Addendum.—While this manuscript was under re-
view, Nature Genetics published “Roberts Syndrome Is
Caused by Mutations in ESCO2, a Human Homolog of
Yeast ECO1 That Is Essential for the Establishment of
Table 2
Homozygosity Mapping of Patients
MARKER
LOCATIONa
(Mb)
RESULTS OF MAPPING FOR AFFECTED
PATIENTS WHO WERE
Band
Unrelated
From an Isolated
Community
R20 Srsym1 Srsym2 R23/LB1 S4134
D8S264 2.1 HT HT HT HT HT 8p23.3
D8S1099 6.1 HT HM HT HT HM 8p23.2
D8S277 6.5 HT HM HM HM HM 8p23.1
D8S1469 9.1 HT HT HT HT HT 8p23.1
D8S550 10.9 HT HM HM HT HT 8p23.1
D8S1130 11.9 HT HT HT HT HT 8p23.1
D8S1106 12.9 HM HT HM HT HT 8p22
D8S511 14.7 HM HT HT HM HT 8p22
D8S549 15.7 HM HM HT HM HM 8p22
D8S1145 18.4 HT HM HT HT HT 8p22
D8S258 20.4 HT HM HT HT HM 8p21.3
D8S282 21.4 HM HM HM HT HT 8p21.3
D8S1116 21.4 HM HM HT HT HT 8p21.3
D8S136 22.5 HM HM HT HT HT 8p21.3
D8S1786 22.5 HM HM HM HT HT 8p21.3
D8S1733 22.6 HM HM HM HT HM 8p21.3
D8S1752 22.7 HM HM HT HM HT 8p21.3
D8S1734 22.9 HM HM HT HT HT 8p21.3
AF279339b 23.3 HM HM HT HM Not done 8p21.3
AC044891b 24.2 HM HM HM HM Not done 8p21.2
AC024958b 24.4 HM HM HM HM Not done 8p21.2
D8S1989 24.7 HM HM HM HM HT 8p21.2
D8S1725 25.1 HM HM HM HM HT 8p21.2
D8S1771 25.5 HM HM HM HM HM 8p21.2
DOCK5ca10b 25.5 HM HM HM HM Not done 8p21.2
D8S382 26.3 HM HM HM HM HM 8p21.2
PPP2R2Ac 26.3 HM HM HM HM Not done 8p21.2
D8S1048 26.0 HM HM HM HM HM 8p21.2
PTK2Bd 27.3 HM HM HM HM HM 8p21.2
Exon 26e 27.4 HM HM HM HM HM 8p21.2
D8S131f 27.4 HM HM HM HM HM 8p21.2
D8S1839 27.4 HM HM HM HM HT 8p21.1
SCARA3-F1b 27.5 HM HM HM HM Not done 8p21.1
D8S585 27.6 HM HM HM HM HT 8p21.1
SCARA3-F2b 28.0 HM HM HM HM HM 8p21.1
D8S1820 28.0 HM HM HM HM HT 8p21.1
D8S1477 32.2 HM HM HT HT HT 8p12
D8S505 34.6 HM HM HT HT HT 8p12
D8S1121 35.9 HM HM HT HT HT 8p12
D8S1747 37.1 HM HM HM HT HT 8p12
D8S1821 38.5 HT HT HT HM HT 8p12
D8S255 40.0 HM HM HT HT HT 8p11.21
D8S1104 40.7 HM HM HT HT HM 8p11.21
D8S532 40.9 HM HM HT HT HT 8p11.21
NOTE.—HM p homozygous; HT p heterozygous.
a Map locations are based on the University of California–Santa Cruz Genome Browser.
b Variable-repeat regions were predicted from the sequence by POPPOUS (Fondon et al. 1998).
c SNP rs3824232: 51 bp before exon 10 splice site (allele frequency unknown).
d SNP rs1045512: exon 2, p.Lys54Lys, Srsym1, Srsym2, and LB1pA (allele frequency 0.775),
R20pG (allele frequency 0.225).
e SNP rs751019: p.Thr838Lys, R20, and LB1pC (allele frequency 0.453); Srsym1 and
Srsym2pA (allele frequency 0.547).
f D8S131: all patients are homozygous for the most common allele (allele frequency 0.791).
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Sister Chromatid Cohesion” (Vega et al. 2005). That
publication describes homozygosity mapping and iden-
tification of the RBS1 gene called “ESCO2.” ESCO2
resides within the 8.9-Mb interval on chromosome 8p21,
as defined in the present study, which confirms that the
disease-causing gene and the locus that can complement
the HR phenotype are one and the same.
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